Interaction #6: 3C-like protease-Etoposide
Computational
positive
Related publications
Title
Author
Type
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong
Research
In Silico Guided Drug Repurposing to Combat SARS-CoV-2 by Targeting Mpro, the Key Virus Specific Protease Ruchi Rani Ankur Singh Akshay Pareek Shailly Tomar
Research
In Silico Molecular Dynamics Docking of Drugs to the Inhibitory Active Site of SARS-CoV-2 Protease and Their Predicted Toxicology and ADME Leif Peterson
Research
Profiling Molecular Simulations of SARS-CoV-2 Main Protease (Mpro) Binding to Repurposed Drugs Using Neural Network Force Fields Aayush Gupta
Research
SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs Shiv Bharadwaj, Esam Ibraheem Azhar, Mohammad Amjad Kamal, Leena Hussein Bajrai, Amit Dubey, Kanupriya Jha, Umesh Yadava, Sang Gu Kang, Vivek Dhar Dwivedi
Research
Computational Estimation of Potential Inhibitors from the Known Drugs against the Main Protease of SARS-CoV-2 Nguyen Minh Tam, Pham Minh Quan, Nguyen Xuan Ha, Pham Cam Nam, Huong Thi Thu Phung
Research
Profiling SARS-CoV-2 Main Protease (MPRO) Binding to Repurposed Drugs Using Molecular Dynamics Simulations in Classical and Neural Network-Trained Force Fields Aayush Gupta, Huan-Xiang Zhou
Research
Target
Target affiliation
Drug
Type
Result
Target
Target affiliation
Drug
Type
Result
Name
Synonyms
Genes
Origin
Name
Synonyms
Genes
Origin
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Title
Authors
DOI
Source
Article type
Date
Title
Authors
DOI
Source
Article type
Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID.
It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial
